jm9b01446_si_002.csv (3.48 kB)
Download fileLigand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles
dataset
posted on 2019-12-16, 16:27 authored by Yali Sang, Sheng Han, Christophe Pannecouque, Erik De Clercq, Chunlin Zhuang, Fener ChenA series of nondimethylphenyl-diarylpyrimidines with
much lower
cytotoxicities than their dimethyl analogues were developed. Compound B13 with a difluorobiphenyl moiety showed the highest antiviral
activity against WT, mutant strains, and RT. The hydrochloride form
of B13 exhibited an improved water solubility of 5.6
μg/mL compared with ETR (≪1 μg/mL), better stability
in human and rat liver microsomes, and a great oral bioavailability
of 44%, making it promising as a drug candidate. In addition, no apparent
toxicity was observed in the acute toxicity assay (2 g/kg) and HE
staining.
History
Usage metrics
Read the peer-reviewed publication
Categories
Keywords
ETROral Pharmacokinetic ProfilesseriesMetabolic StabilitystabilitystrainWTSafetystainingdifluorobiphenyl moietycytotoxicitiedrug candidate5.6Nondimethylphenyl-DiarylpyrimidineLigand-Based DesignRTassaybioavailabilityhydrochloride formnondimethylphenyl-diarylpyrimidinewater solubilityrat liver microsomesdimethyl analoguesCompound B 13toxicityB 13
CC BY-NC 4.0